{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-018228","form_type":"8-K","ticker":"KALA","cik":"0001479419","company_name":"KALA BIO, Inc.","filed_at":"2022-11-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.800205+00:00","generated_at":"2026-06-21T12:41:46.626058+00:00","sec_items":["1.01","5.03","3.02","3.03","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Kala Pharma raises up to $31M in private placement; submits IND for KPI-012","bullets":["First closing gross proceeds ~$6M: 76,813 common shares at $5.75 and 9,666 Series E preferred shares at $575 each.","Second closing ~$25M (Series E preferred) contingent on FDA acceptance of IND for KPI-012 by March 31, 2023.","IND submitted for KPI-012 to treat persistent corneal epithelial defects; Phase 2b trial start in Q4 2022, topline data expected Q1 2024.","Cash runway extended into Q1 2025 assuming both closings occur.","Series E preferred stock convertible into common at 100:1, senior to common; all outstanding Series D preferred eliminated."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-018228","json":"https://secwatch.observer/filing/0001558370-22-018228.json","markdown":"https://secwatch.observer/filing/0001558370-22-018228.md","text":"https://secwatch.observer/filing/0001558370-22-018228.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1479419/000155837022018228/0001558370-22-018228-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1479419/000155837022018228/kala-20221128x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T12:41:46.626058+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"25f271bebd1aedf4f92afe3a82397851946c5d28","claim":"KALA BIO, Inc.: Filed Certificate of Elimination to remove all matters related to Series D Preferred Stock and reclassify shares as undesignated preferred stock (effective 2022-11-28).","evidence_excerpt":"On November 28, 2022, immediately prior to filing the Certificate of Designation referenced above, the Company filed a Certificate of Elimination of Number of Shares of Preferred Stock Designated as Series D Preferred Stock (the “Certificate of Elimination”) with the Secretary of State of the State of Delaware which, effective upon filing, eliminated all matters set forth in the Certificate of Designation of Series D Preferred Stock previously filed by the Company and all shares of Preferred Stock previously designated as Series D Preferred Stock resumed their status as undesignated shares of preferred stock of the Company.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1479419/000155837022018228/0001558370-22-018228-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2022-11-28"}],"fact_type":"governance_change"},{"claim_id":"27d1a1b98609154f1f6eaa6e0d539b65481ae520","claim":"KALA BIO, Inc.: Filed Certificate of Designations to establish Series E Convertible Non-Redeemable Preferred Stock (effective 2022-11-28).","evidence_excerpt":"On November 28, 2022 (the “Filing Date”), the Company filed a Certificate of Designations, Preferences and Rights of Series E Convertible Non-Redeemable Preferred Stock (the “Certificate of Designations”) with the Secretary of State of the State of Delaware with respect to the Series E Preferred Stock.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1479419/000155837022018228/0001558370-22-018228-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2022-11-28"}],"fact_type":"governance_change"},{"claim_id":"59107f0c9afc3428728e561941a38aa1495c996a","claim":"KALA BIO, Inc. entered into Securities Purchase Agreement with certain institutional investors valued at aggregate gross proceeds of up to $31.0 million (effective 2022-11-28).","evidence_excerpt":"On November 28, 2022, Kala Pharmaceuticals, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain institutional investors named therein (the “Purchasers”), pursuant to which the Company agreed to issue and sell, in a private placement priced at-the-market under Nasdaq rules, shares (the “Common Shares”) of Common Stock, par value $0.001 per share, of the Company (the “Common Stock”) and shares (the “Preferred Shares”, and together with the Common Shares, the “Private Placement Shares”) of Series E Convertible Non-Redeemable Preferred Stock, par value $0.001 per share, of the Company (the “Series E Preferred Stock”), in two tranches for aggregate gross proceeds of up to $31.0 million (collectively, the “Private Placement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1479419/000155837022018228/0001558370-22-018228-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional investors"},{"label":"Value","value":"aggregate gross proceeds of up to $31.0 million"},{"label":"Effective","value":"2022-11-28"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}